Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Several studies have demonstrated that IFN-I administration can boost anti-tumor immune response against solid tumors. Here, to overcome the limitations of systemic IFN-I therapy (side effects, short half-life), the authors design a masked IFN-I prodrug activatable by tumor-associated proteases, sho...

Full description

Bibliographic Details
Main Authors: Xuezhi Cao, Yong Liang, Zhenxiang Hu, Huiyu Li, Jiaming Yang, Eric J. Hsu, Jiankun Zhu, Jin Zhou, Yang-Xin Fu
Format: Article
Language:English
Published: Nature Publishing Group 2021-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-26112-2

Internet

https://doi.org/10.1038/s41467-021-26112-2

Similar Items